Business Context and Reporting Period
Creative Medical Technology Holdings, Inc., a Nevada corporation, filed this Form 8-K on March 11, 2021. The report details corporate governance changes regarding preferred stock rights and operational updates concerning its StemSpine® Regenerative Stem Cell Procedure.
Key Financial Metrics
This filing is a current report regarding specific events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- Amendment to Series A Preferred Stock: The Company filed a Certificate of Amendment increasing the voting power of its Series A Preferred Stock from 30 votes per share to 1,000 votes per share.
- Ownership Concentration: All 3,000,000 outstanding shares of Series A Preferred Stock are held by Timothy Warbington, the Company's Chief Executive Officer.
- Clinical Trial Progress: The Company announced the commencement of recruitment for clinical sites to treat patients with Degenerative Disc Disease using its StemSpine® procedure.
Outlook, Risks, and Management Commentary
Management highlighted the initiation of clinical site recruitment as a key operational milestone. The amendment to the voting rights of the Series A Preferred Stock significantly alters the control structure of the Company, concentrating voting power with the CEO. No specific financial guidance or risk factors beyond the standard incorporation by reference of the amendment terms were detailed in the text of this filing.
Investor Verification Checklist
- Verify the full terms of the Certificate of Amendment (Exhibit 3.1) to understand any other rights or restrictions attached to the increased voting power.
- Confirm the timeline and criteria for the StemSpine® clinical trial recruitment announced in the March 10, 2021 press release (Exhibit 99.1).
- Review the Company's most recent 10-K or 10-Q filings for financial data, as this 8-K contains no financial metrics.
- Assess the implications of the CEO holding 100% of the Series A Preferred Stock with 1,000 votes per share on future corporate governance decisions.